Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Kiniksa Pharmaceuticals International (KNSA) management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16, 2026.
The London session is scheduled for 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time). A live webcast will be available through the Investors section of Kiniksa’s website, with a replay available within approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported third-quarter 2026 ARCALYST net product revenue of $286.0 million, representing approximately 58% year-over-year growth. Net income rose to $47.3 million from $18.4 million, while diluted earnings per share increased to $0.56 from $0.23. Kiniksa raised its expected 2026 ARCALYST revenue to $1.045–$1.050 billion, from $980–$995 million.
Cash, cash equivalents and short-term investments totaled $568.8 million at September 30, with no debt. Quarterly operating expenses increased to $231.7 million from $156.8 million. Kiniksa expects its operating plan to remain cash flow positive annually. Enrollment and dosing continue in the pivotal KPL-387 PASTORALE trial, with data expected in the second half of 2027. The company expects to begin a first-in-human KPL-1161 trial by the end of 2026.
Kiniksa Pharmaceuticals (KNSA) will report third quarter 2026 financial results during a conference call and live webcast on October 27, 2026. The event begins at 8:30 a.m. Eastern Time and will also cover recent portfolio execution. The webcast will be available through the Investors & Media section of Kiniksa’s website, with a replay available within approximately 48 hours after the event.
Kiniksa Pharmaceuticals (KNSA) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. Eastern Time.
A live webcast of the presentation will be available via the Investors section of Kiniksa’s website, with a replay accessible on the site approximately 48 hours after the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast and replay will be available in the Investors section of Kiniksa’s website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q2 2026 total revenue of $243.6 million, all from ARCALYST, up about 55% year over year. Net income was $25.4 million versus $17.8 million a year earlier, with operating expenses rising to $216.4 million.
ARCALYST Q2 net product revenue was $243.6 million, and 2026 net product revenue guidance was raised to $980–$995 million, from $930–$945 million, according to Kiniksa. Cash, cash equivalents, and short-term investments were $525.9 million with no debt as of June 30, 2026.
KPL-387 Phase 2 data in recurrent pericarditis showed rapid median time to treatment response of 4 days at 300 mg SC monthly, supporting this dose for the pivotal Phase 3 PASTORALE trial, which is now enrolling. Kiniksa also plans to start a Phase 1 trial of KPL-1161 by year-end 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern Time to report its second quarter 2026 financial results and recent portfolio execution. The live webcast and replay will be available via the Investors & Media section of Kiniksa’s website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in investor fireside chats at two June 2026 healthcare conferences: the Jefferies Global Healthcare Conference on June 3 at 8:45 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET.
Live webcasts and replays will be available via the Investors & Media section of Kiniksa's website.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) reported Q1 2026 results with ARCALYST net product revenue of $214.3M, a 56% year-over-year increase, and raised 2026 ARCALYST guidance to $930–$945M. Q1 net income was $22.6M. Cash and short-term investments totaled $468.1M with no debt. Clinical milestones: KPL-387 Phase 2 data expected in 2H 2026 and Phase 3 initiation targeted by year-end; KPL-1161 Phase 1 planned by end of 2026.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) will report first quarter 2026 financial results on April 28, 2026 with a conference call and live webcast at 8:30 a.m. ET.
Telephone registration is required; webcast and a replay (available ~48 hours after the event) will be accessible via the company website.